| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Metabolite of taurocholic acid
|
|---|---|
| References | |
| Additional Infomation |
Sortilin 1 (Sort1) is an intracellular transport receptor that mediates protein sorting in endocytosis or secretion pathways. Recent studies have revealed the role of Sort1 in the regulation of cholesterol and bile acid (BA) metabolism. This study further investigated the regulatory role of Sort1 in BA detoxification and cholestatic liver injury in bile duct ligation mice. We found that Sort1 knockout (KO) mice showed reduced liver injury 24 hours after bile duct ligation (BDL), mainly attributed to reduced bile infarction formation. The BA pool volume of Sort1 KO mice in the sham-operated group was approximately 20% higher than that of wild-type (WT) mice in the sham-operated group, but 24 hours after BDL, the liver BA accumulation and BA pool volume of Sort1 KO mice were significantly reduced. Fourteen days after bile duct ligation (BDL), the concentration of bile acids (BA) in the liver of Sort1 knockout (KO) mice was significantly reduced, and the expression of inflammation and fibrosis marker genes was also reduced, but the degree of liver fibrosis was similar to that of wild-type (WT) mice. Unbiased quantitative proteomics analysis showed that the level of bile acid sulfotransferase 2A1 (BS2A1) in the liver of Sort1 KO mice was increased, but the levels of phase I bile acid metabolism cytochrome P450 or phase III bile acid efflux transporter were not changed. Consistent with this, the plasma taurocholic acid sulfate level of Sort1 KO mice was increased after BDL. Finally, we found that Sort1 expression in the liver was inhibited after BDL, which may be due to the activation of farnesol X receptor by bile acids. In summary, we reported the role of Sort1 in the regulation of bile acid detoxification and cholestatic liver injury in mouse liver. The mechanism of increased bile acid clearance in the liver of Sort1 KO mice after BDL needs further investigation. [1]
|
| Molecular Formula |
C26H43NNA2O10S2
|
|---|---|
| Molecular Weight |
639.729868173599
|
| Exact Mass |
639.2123
|
| CAS # |
71781-33-4
|
| PubChem CID |
155970342
|
| Appearance |
Typically exists as solids at room temperature
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
41
|
| Complexity |
1090
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
S(=O)(=O)([O-])O[C@@H]1CC[C@@]2(C)[C@@H](C1)C[C@H]([C@@H]1[C@@H]2C[C@@H]([C@]2(C)[C@@H]([C@H](C)CCC(NCCS(=O)(=O)[O-])=O)CC[C@H]21)O)O.[Na+].[Na+]
|
| InChi Key |
JDZGOMAYFRJNTP-NEMAEHQESA-L
|
| InChi Code |
InChI=1S/C26H45NO10S2.2Na/c1-15(4-7-23(30)27-10-11-38(31,32)33)18-5-6-19-24-20(14-22(29)26(18,19)3)25(2)9-8-17(37-39(34,35)36)12-16(25)13-21(24)28;;/h15-22,24,28-29H,4-14H2,1-3H3,(H,27,30)(H,31,32,33)(H,34,35,36);;/q;2*+1/p-2/t15-,16+,17-,18-,19+,20+,21-,22+,24+,25+,26-;;/m1../s1
|
| Chemical Name |
disodium;2-[[(4R)-4-[(3R,5R,7R,8R,9S,10S,12S,13R,14S,17R)-7,12-dihydroxy-10,13-dimethyl-3-sulfonatooxy-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate
|
| Synonyms |
3-Sulfocholyl Taurine; 3-Sulfo-taurocholicAcidDisodiumSalt; 71781-33-4; 3-Sulfo-taurocholic Acid Disodium Salt; disodium;2-[[(4R)-4-[(3R,5R,7R,8R,9S,10S,12S,13R,14S,17R)-7,12-dihydroxy-10,13-dimethyl-3-sulfonatooxy-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate; PD143592; TCA3S
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5632 mL | 7.8158 mL | 15.6316 mL | |
| 5 mM | 0.3126 mL | 1.5632 mL | 3.1263 mL | |
| 10 mM | 0.1563 mL | 0.7816 mL | 1.5632 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
